Mon panier

Biotinylated Human 4-1BB / TNFRSF9 (24-86) Protein, His,Avitag™

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
41B-H82E9-25ug
$360.00
41B-H82E9-200ug
$1565.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    TNFRSF9, 4-1BB, CD137, CDw137, ILA

  • Source

    Biotinylated Human 4-1BB (24-86), His,Avitag (41B-H82E9) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Cys 86 (Accession # Q07011-1).

    Predicted N-terminus: Leu 24

    Request for sequence
  • Molecular Characterization

    4-1BB Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 10.4 kDa. The protein migrates as 14-16 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    4-1BB SDS-PAGE

    Biotinylated Human 4-1BB (24-86), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     4-1BB ELISA

    Immobilized Biotinylated Human 4-1BB (24-86), His,Avitag (Cat. No. 41B-H82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind UreluMab Human IgG4 with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol
  •  4-1BB ELISA

    Immobilized UreluMab Human IgG4 at 1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB (24-86), His,Avitag (Cat. No. 41B-H82E9) with a linear range of 1-39 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Tumor necrosis factor receptor superfamily member 9

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    77 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte